If validated, the risk score could help guide decisions around surveillance and risk-reduction treatments for patients with in situ breast disease.

Treatment for early-stage breast cancer is one of the great debates—and now, there’s been incredible progress in understanding whether women diagnosed with stage zero breast cancer, known as ductal ...

At just 36 years old, Constance “Connie” Chavis learned she had stage 3 breast cancer — a combination of ductal carcinoma in ...

The first study comparing surgery to active monitoring as treatment for ductal carcinoma in situ (DCIS) finds women who carefully monitor the precancerous cells are no more likely to develop breast ...

A new study published in Cancer Epidemiology, Biomarkers (and) Prevention, a journal of the American Association for Cancer ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced that Laura J. Esserman, MD ...

Please provide your email address to receive an email when new articles are posted on . Results showed a lower 2-year cumulative rate of invasive ipsilateral breast cancer among patients assigned ...

Breast cancer is not a single disease but multiple ones, each carrying varying degrees of risk for endangering women’s health. In recent years, many researchers have been focused on DCIS: ductal ...

When 45-year-old Kim Burris was recovering from breast reduction surgery at home in Chapel Hill, she received a call that ...

There was no significant association between circulating levels of serum 25-hydroxyvitamin D (25[OH]D) and the risk of ductal carcinoma in situ (DCIS) of the breast, either overall or by menopausal ...

Mar. 24 -- TUESDAY, Feb. 12 (HealthDay News) -- Many women diagnosed with a precancerous breast lesion known as ductal carcinoma in situ (DCIS) are highly anxious about their prognosis, even though ...